These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 38325664

  • 1. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J, Porenta D, Wilbie D, Seinen C, Benne N, Yang Q, de Jong OG, Lei Z, Mastrobattista E.
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [Abstract] [Full Text] [Related]

  • 2. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
    Mirjalili Mohanna SZ, Djaksigulova D, Hill AM, Wagner PK, Simpson EM, Leavitt BR.
    J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
    [Abstract] [Full Text] [Related]

  • 3. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D, Walther J, Mastrobattista E.
    Acc Chem Res; 2019 Jun 18; 52(6):1555-1564. PubMed ID: 31099553
    [Abstract] [Full Text] [Related]

  • 4. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.
    Liu J, Chang J, Jiang Y, Meng X, Sun T, Mao L, Xu Q, Wang M.
    Adv Mater; 2019 Aug 18; 31(33):e1902575. PubMed ID: 31215123
    [Abstract] [Full Text] [Related]

  • 5. Guanidinium-Rich Lipopeptide-Based Nanoparticle Enables Efficient Gene Editing in Skeletal Muscles.
    Zhu M, Wang X, Xie R, Wang Y, Xu X, Burger J, Gong S.
    ACS Appl Mater Interfaces; 2023 Mar 01; 15(8):10464-10476. PubMed ID: 36800641
    [Abstract] [Full Text] [Related]

  • 6. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
    Zhang S, Shen J, Li D, Cheng Y.
    Theranostics; 2021 Mar 01; 11(2):614-648. PubMed ID: 33391496
    [Abstract] [Full Text] [Related]

  • 7. Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 RNP.
    Chen K, Han H, Zhao S, Xu B, Yin B, Trinidad M, Burgstone BW, Murthy N, Doudna JA.
    bioRxiv; 2023 Nov 15. PubMed ID: 38014175
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.
    Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, Dirstine T, Ciullo C, Lescarbeau R, Seitzer J, Shah RR, Shah A, Ling D, Growe J, Pink M, Rohde E, Wood KM, Salomon WE, Harrington WF, Dombrowski C, Strapps WR, Chang Y, Morrissey DV.
    Cell Rep; 2018 Feb 27; 22(9):2227-2235. PubMed ID: 29490262
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Physicochemical and Functional Characterization of Differential CRISPR-Cas9 Ribonucleoprotein Complexes.
    Camperi J, Moshref M, Dai L, Lee HY.
    Anal Chem; 2022 Jan 18; 94(2):1432-1440. PubMed ID: 34958212
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of Formulation Conditions on Lipid Nanoparticle Characteristics and Functional Delivery of CRISPR RNP for Gene Knock-Out and Correction.
    Walther J, Wilbie D, Tissingh VSJ, Öktem M, van der Veen H, Lou B, Mastrobattista E.
    Pharmaceutics; 2022 Jan 17; 14(1):. PubMed ID: 35057110
    [Abstract] [Full Text] [Related]

  • 15. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing.
    Chen G, Abdeen AA, Wang Y, Shahi PK, Robertson S, Xie R, Suzuki M, Pattnaik BR, Saha K, Gong S.
    Nat Nanotechnol; 2019 Oct 17; 14(10):974-980. PubMed ID: 31501532
    [Abstract] [Full Text] [Related]

  • 16. Precision Genome Editing with CRISPR-Cas9.
    Rahman S, Ikram AR, Azeem F, Tahir Ul Qamar M, Shaheen T, Mehboob-Ur-Rahman.
    Methods Mol Biol; 2024 Oct 17; 2788():355-372. PubMed ID: 38656525
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. RNA lipid nanoparticles as efficient in vivo CRISPR-Cas9 gene editing tool for therapeutic target validation in glioblastoma cancer stem cells.
    Rouatbi N, Walters AA, Costa PM, Qin Y, Liam-Or R, Grant V, Pollard SM, Wang JT, Al-Jamal KT.
    J Control Release; 2024 Nov 17; 375():776-787. PubMed ID: 39284526
    [Abstract] [Full Text] [Related]

  • 19. Precision genome editing in the CRISPR era.
    Salsman J, Dellaire G.
    Biochem Cell Biol; 2017 Apr 17; 95(2):187-201. PubMed ID: 28177771
    [Abstract] [Full Text] [Related]

  • 20. Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.
    Sun Q, Zhang H, Ding F, Gao X, Zhu Z, Yang C.
    Int J Pharm; 2024 Mar 05; 652():123845. PubMed ID: 38266942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.